RxDoctor Payments Data

Timothy Wright

Physician Assistant · Bloomfield, CTNPI 1619405669

Payments from drug & device makers

$1,756in general payments, 2019–2025

Across 73 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$305
  • Abbott$237
  • E.r. Squibb & Sons, L.L.C.$210
  • Bayer$205
  • Novartis$183
  • AstraZeneca$170
  • plus $446 from 8 others

What the payments were for

  • Food & beverage$1,73599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,756 in reported general payments places this provider in the 85th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,175
Medicare patients
129
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan221$268,870
CamzyosMavacamten30$265,552
FarxigaDapagliflozin Propanediol151$168,636
JardianceEmpagliflozin100$124,539
EliquisApixaban28$19,510
Torsemide222$6,515
Metoprolol Succinate126$1,634
Bumetanide20$1,479
Spironolactone218$1,455
Potassium Chloride45$784
Carvedilol92$668
Klor-Con M20Potassium Chloride31$503
Valsartan26$444
Furosemide108$382
ClopidogrelClopidogrel Bisulfate14$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$183$268,870221 claims
E.r. Squibb & Sons, L.L.C.Camzyos$210$265,55230 claims
AstraZenecaFarxiga$170$168,636151 claims
Boehringer IngelheimJardiance$163$124,539100 claims
PfizerEliquis$305$19,51028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →